ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SYNC Syncona Limited

122.80
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Syncona Limited LSE:SYNC London Ordinary Share GG00B8P59C08 ORD NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 122.80 122.40 124.20 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Trust,ex Ed,religious,charty -39.79M -56.02M -0.0840 -14.62 818.75M

Syncona Limited Autolus publishes Annual Report (4668I)

26/11/2018 9:57am

UK Regulatory


Syncona (LSE:SYNC)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Syncona Charts.

TIDMSYNC

RNS Number : 4668I

Syncona Limited

26 November 2018

Syncona Limited

Autolus publishes Annual Report

26 November 2018

Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today notes that its portfolio company, Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced that it has filed its annual report on Form 20-F for the fiscal year ended 2018 with the United States Securities and Exchange Commission.

The announcement can be found below and the annual report can be found on Autolus' investor relations website at https://www.autolus.com/investor-relations/financial-information/sec-filings.

[ENDS]

Enquiries

Syncona Ltd

Annabel Clay

Tel: +44 (0) 20 7611 2010

Tulchan Communications

Martin Robinson

Lisa Jarrett-Kerr

Tel: +44 (0) 207 353 4200

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com

About Syncona

Syncona is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.

We take a long-term view, underpinned by a deep pool of capital, and are established leaders in the development of genetic medicine, particularly gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.

About Autolus

Autolus is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer.

Autolus Therapeutics Submits Fiscal Year 2018 Form 20-F

LONDON, November 23, 2018 -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended 2018 with the United States Securities and Exchange Commission. The annual report can be found on Autolus' investor relations website at https://www.autolus.com/investor-relations/financial-information/sec-filings.

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, go to: https://www.autolus.com

# #

Investor contact:

S.A. Noonan Communications

Susan A. Noonan

+1-212-966-3650

susan@sanoonan.com

International Media Contact:

JW Communications

Julia Wilson

+44 (0)7818 430877

juliawilsonuk@gmail.com

U.S. Media Contact:

Rx Communications Group, LLC

Paula Schwartz

+ 1-917-322-2216

pschwartz@rxir.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

PFUGCBDBBUDBGIL

(END) Dow Jones Newswires

November 26, 2018 04:57 ET (09:57 GMT)

1 Year Syncona Chart

1 Year Syncona Chart

1 Month Syncona Chart

1 Month Syncona Chart

Your Recent History

Delayed Upgrade Clock